TY  - JOUR

T1  - HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

JO  - eBioMedicine

PY  - 2022/08/11

AU  - Bergamino MA

AU  - López-Knowles E

AU  - Morani G

AU  - Tovey H

AU  - Kilburn L

AU  - Schuster EF

AU  - Alataki A

AU  - Hills M

AU  - Xiao H

AU  - Holcombe C

AU  - Skene A et al

ED  - 

DO  - DOI: 10.1016/j.ebiom.2022.104205

PB  - Elsevier BV

SP  - 104205

EP  - 104205

Y2  - 2024/12/22

ER  -